Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model.

Janine Mühe, Pyone Pyone Aye, Carol Quink, Jing Ying Eng, Kathleen Engelman, Keith A Reimann, Fred Wang

Cell reports. Medicine 2021 Jul 20

filter terms:

Epstein-Barr virus (EBV) and related lymphocryptoviruses (LCVs) from nonhuman primates are transmitted through oral secretions, penetrate the mucosal epithelium, and establish persistent infection in B cells. To determine whether neutralizing antibodies against epithelial or B cell infection could block oral transmission and persistent LCV infection, we use rhesus macaques, the most accurate animal model for EBV infection by faithfully reproducing acute and persistent infection in humans. Naive animals are infused with monoclonal antibodies neutralizing epithelial cell infection or B cell infection and then challenged orally with recombinant rhesus LCV. Our data show that high-titer B cell-neutralizing antibodies alone, but not epithelial cell-neutralizing antibodies, can provide complete protection of rhesus macaques from oral LCV challenge, but not in all hosts. Thus, neutralizing antibodies against B cell infection are important targets for EBV vaccine development, but they may not be sufficient. © 2021 The Author(s).

Citation

Janine Mühe, Pyone Pyone Aye, Carol Quink, Jing Ying Eng, Kathleen Engelman, Keith A Reimann, Fred Wang. Neutralizing antibodies against Epstein-Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model. Cell reports. Medicine. 2021 Jul 20;2(7):100352